Edition:
India

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

30.40USD
23 Jan 2018
Change (% chg)

$0.96 (+3.26%)
Prev Close
$29.44
Open
$29.49
Day's High
$30.50
Day's Low
$29.49
Volume
735,372
Avg. Vol
957,860
52-wk High
$32.49
52-wk Low
$16.72

Select another date:

Wed, Jan 17 2018

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics

* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS

BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab

* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

Pfizer, Exelixis cancer drugs get FDA approval for wider use

Dec 19 Cancer treatments from Pfizer Inc and Exelixis Inc on Tuesday won approval from the U.S. Food and Drug Administration for expanded use in previously untreated patients.

BRIEF-Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma

* EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC

* FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update

Exelixis drug improves overall survival in liver cancer patients

Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent.

BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial

* Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Select another date: